ADVFN US – Market Content Editor
-

Small caps and homebuilders most at risk if Fed delivers hawkish surprise at Jackson Hole
Small-cap stocks and homebuilders could face the greatest downside if the Federal Reserve signals a hawkish stance at this week’s Jackson Hole symposium, according to Barclays. Barclays’ economists continue to take a contrarian view, expecting no rate cut in September. “With some segments of the equity market having moved swiftly to reprice rates from ‘higher…
-

Rocket Pharmaceuticals surges as FDA lifts clinical hold on Phase 2 trial
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) jumped 23% after the U.S. Food and Drug Administration lifted the clinical hold on the company’s pivotal Phase 2 trial of RP-A501 for treating Danon disease. The FDA removed the hold in less than three months, confirming that Rocket had adequately addressed the agency’s prior concerns. The study is…
-

GDS Holdings shares rise 4% after Q2 revenue exceeds expectations
GDS Holdings Limited (NASDAQ:GDS) saw its shares climb 3.93% in pre-market trading on Wednesday after the China-based data center developer and operator reported second-quarter results that surpassed analyst forecasts, driven by ongoing expansion of its data center operations. The company posted a net loss of RMB0.06 per share for Q2, far better than the estimated…
-

TJX shares climb as strong Q2 results prompt higher full-year outlook
The TJX Companies (NYSE:TJX) saw shares rise 3.8% after reporting second-quarter results that surpassed analyst expectations, leading the off-price retailer to raise its full-year profit guidance. The parent company of T.J. Maxx, Marshalls, and HomeGoods posted adjusted earnings per share of $1.10 for the quarter, well above the $1.01 analysts had anticipated. Revenue reached $14.4…
-

enVVeno Medical shares collapse after FDA denies VenoValve approval
Shares of enVVeno Medical Corporation (NASDAQ:NVNO) plunged roughly 70% following news that the U.S. Food and Drug Administration issued a not-approvable letter for the company’s VenoValve device. The FDA concluded that the Premarket Approval (PMA) application for VenoValve—a surgical venous valve replacement intended to treat severe chronic deep venous insufficiency—could not be approved in its…
-

Snowflake gains after BofA upgrade to Buy, boosted by AI growth outlook
Shares of Snowflake (NYSE:SNOW) advanced on Wednesday after Bank of America Securities raised its rating on the data cloud company to Buy from Neutral, while lifting its price target to $240 from $220. The upgrade reflects improving demand dynamics and a constructive long-term view tied to artificial intelligence and data services. The new price objective…
-

Hertz Shares Jump on Amazon Autos Partnership; Carvana Slips
Hertz Global Holdings (NASDAQ:HTZ) shares surged 12% in early trading Wednesday after the company unveiled a new partnership with Amazon’s (NASDAQ:AMZN) online auto platform. In contrast, rival Carvana (NYSE:CVNA) saw its stock drop 5.5% following the news. As reported by CNBC, the agreement will allow Hertz to sell its pre-owned vehicles directly through Amazon Autos.…
-

Analog Devices Shares Rise as Q3 Results and Outlook Beat Forecasts
Analog Devices, Inc. (NASDAQ:ADI) saw its stock climb more than 4% in premarket trading Wednesday after reporting third-quarter results that outpaced Wall Street estimates and issuing stronger-than-expected guidance for the current quarter. For Q3, the semiconductor maker delivered adjusted earnings per share of $2.05, above the $1.95 consensus. Revenue reached $2.88 billion, topping expectations of…
-

Jiayin Group Delivers Strong Q2 with Loan Growth Surpassing 54%, Revenue Jumps 27%
Jiayin Group Inc. (NASDAQ:JFIN), a prominent fintech platform based in China, posted robust second-quarter earnings on Wednesday, highlighted by a 54.6% year-over-year surge in loan facilitation volume to RMB37.1 billion (US$5.2 billion). Net revenue climbed 27.8% to RMB1.89 billion (US$263.3 million). Following the report, Jiayin’s shares rose 0.93% in after-hours trading. Operating income soared 181.4%…
-

Dayforce Shares Climb on Confirmation of Takeover Talks with Thoma Bravo
Dayforce (NYSE:DAY) shares gained 2.7% Wednesday morning after the human capital management company confirmed it is in “advanced discussions” with private equity firm Thoma Bravo about a potential buyout. The company disclosed it is negotiating a go-private transaction at a proposed price of US$70 per share. The announcement follows a Bloomberg report earlier this week…